Prostate Cancer Management: Introduction and Overview

Panelists: Raoul S. Concepcion, MD, Urology Associates, PC; Steve Dobbs, Urologic Associates of Oklahoma; Bryan A. Mehlhaff, MD, Oregon Urology Institute; Daniel R. Saltzstein, MD, Urology San Antonio Research;
Neal D. Shore, MD, Atlantic Urology Clinics
Published Online: Wednesday, December 12, 2012
For High-Definition, Click
In the first installment of the series, the moderator, Raoul S. Concepcion, MD, provides an overview of the prostate cancer treatment continuum and introduces the panel, which includes: Steve Dobbs, Bryan A. Mehlhaff, MD, Neal D. Shore, MD, and Daniel R. Saltzstein, MD.

This panel discussion seeks to address a range of challenges facing the treatment of men with prostate cancer. Panelist will discuss a range of topics, from data on the many new treatments for prostate cancer to reimbursement and other practice management issues.

Concepcion provides a summary of the current treatment continuum for men with prostate cancer. He explains that androgen deprivation therapy (ADT) is still used as the early treatment for advancing prostate cancer in patients who have failed definitive therapy. In general, ADT lowers androgen levels and stops the growth of prostate cancer cells. However, patients will eventually fail ADT, which manifests in a raise in PSA levels. Following the failure of hormonal therapy, urologists have traditionally referred patients to medical oncologists.
View More From This Discussion
Episode 1 Prostate Cancer Management: Introduction and Overview
Episode 2 Managing ADT-Associated Skeletal-Related Events
Episode 3 Immunotherapy in Advanced Prostate Cancer, Part I
Episode 4 Immunotherapy in Advanced Prostate Cancer, Part II
Episode 5 NCCN Guidelines for Advanced Prostate Cancer
Episode 6 Treatments for Post-Docetaxel Prostate Cancer, Part I
Episode 7 Treatments for Post-Docetaxel Prostate Cancer, Part II
Episode 8 Emerging Therapies in Prostate Cancer
Episode 9 Dr. Shore Reviews Emerging Therapies in Prostate Cancer
Episode 10 Management of Patients with Advanced Prostate Cancer
Episode 11 Dr. Shore Discusses Therapy Combination in CRPC
Episode 12 Dr. Shore on the Management of Patients with CRPC
Episode 13 Reimbursement Issues in Prostate Cancer, Part I
Episode 14 Reimbursement Issues in Prostate Cancer, Part II
Episode 15 Revenue Opportunities and GPOs for Urology Groups
Episode 16 Dr. Shore on Current Clinical Trial Challenges in CRPC
Episode 17 Effective Management of Prostate Cancer Conclusion
Expert Panelists
Raoul S. Concepcion

Raoul S. Concepcion, MD

Urologists in Cancer Care
Director of Clinical Research
Urologic Surgeon
Urology Associates, PC
Nashville, TN

Steve Dobbs

CEO, Urologic Associates of Oklahoma,
Tulsa, Oklahoma

Bryan A. Mehlhaff, MD

Principal Investigator, Division of Clinical Research, Oregon Urology Institute, Springfield, Oregon

Neal D. Shore, MD

Director, CPI, Carolina Urologic Research Center, Grand Strand Urology/Atlantic Urology Clinics, Myrtle Beach,
South Carolina

Daniel R. Saltzstein, MD

Medical Director, Urology San Antonio Research, San Antonio, Texas
Online CME Activities
Free CME from PER
PARP Inhibitors: Current and Future Options for Breast and Ovarian Cancer
Rapid Summaries and Commentaries: Update from Chicago - Advances in the Treatment of Lung Cancer
Medical Crossfire®: The JAK-STAT Pathway as a Mediator of Onco-Inflammation
2nd Annual Miami Lung Cancer Conference™ Medical Crossfire® Case Discussion
The content contained in this video is for general information purposes only. The viewer is encouraged to confirm the information presented with other sources. OncLiveTV Peer Exchange makes no representations or warranties of any kind about the completeness, accuracy, timeliness, reliability, or suitability of any of the information, including content or advertisements, contained in this video and expressly disclaims liability for any errors and omissions that may be presented in this video. OncLiveTV Peer Exchange reserves the right to alter or correct any error or omission in the information it provides in this video, without any obligations. OncLiveTV Peer Exchange further disclaims any and all liability for any direct, indirect, consequential, special, exemplary, or other damages arising from the use or misuse of any material or information presented in this video. The views expressed in this video are those of the panelists and do not necessarily reflect the opinion or policy of OncLiveTV Peer Exchange.
More Reading